Drug discovery firm in US office move

Sygnature Discovery's new US office at 245 First Street, Cambridge, MA

Nottingham drug discovery company Sygnature Discovery has moved into a new office in Cambridge, Massachusetts as it looks to make further inroads into the North American market.

The firm’s new office at 245 First Street is near Kendall Square in the heart of the Cambridge-Boston biotech hub, where more than 100 pharma and biotech companies are located.

According to Sygnature’s director of marketing Anders Lindstrom, the company has chosen to move into new premises just a short distance from its previous US office in Harvard Square because it wants to maximise the potential for collaboration offered by the hub.

He said: ‘We have seen the benefits of having a physical presence in Harvard Square, and it has served us really well.

“The opportunity to move closer to the Kendall Square centre of the biotech cluster was one we could not pass up. One of our key strengths is our collaborative approach to drug discovery, and a physical presence as close as possible to customers is important, so this crucible of drug discovery is the perfect place for us.”

Sygnature, which has been involved in the US market for 15 years, has reported increased demand from US companies ranging from big pharma to small university spinouts.

The firm’s senior vice-president of business development Paul Clewlow added: “We believe the services and expertise we have within Sygnature is perfectly tuned to providing the resource and expertise our customers need to take forward their innovative drug discovery programmes. A huge amount of exciting drug discovery is going on in the Boston-Cambridge area – not just biotechs, but big pharma is congregating there now as well. It is a great hub for us from where to better serve our North American customer base.”

Click here to sign up to receive our new South West business news...
Close